Sanofi Halts Amlitelimab Development After Disappointing Phase 3 Trial Data

Sanofi (EPA:SASY) announced Friday it will discontinue the development of its experimental drug amlitelimab and will not seek regulatory approval. The decision follows the release of mixed results from its Phase 3 clinical trials which failed to meet key endpoints.

Trial Results Prompt Strategic Shift

The French pharmaceutical giant cited weaker-than-expected efficacy and some safety concerns that emerged during late-stage testing as the primary reasons for halting the program. As a result, Sanofi confirmed it will not proceed with global regulatory filings for the drug.

This move marks a strategic shift from the company's previous management team, which had remained committed to advancing amlitelimab despite the challenging trial data.

Ad

Implications for Sanofi's Pipeline

The termination of the amlitelimab program was not entirely unexpected by the market. Analysts had previously revised their peak sales forecasts for the asset down to approximately €1 billion amid growing doubts about its clinical profile.

The decision, coming just a week before Sanofi is scheduled to report its second-quarter earnings, is being interpreted by some analysts as a signal of a more rigorous pipeline review. Industry observers now speculate that other assets in Sanofi's development portfolio, such as itepekimab or an oral TNF therapy, could also face discontinuation as the company re-evaluates its R&D priorities.